CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用 TCR-CAR 双信号实现肿瘤精准靶向
英文原题：Using TCR-CAR dual signaling for precise cancer targeting.
查看英文原题
Using TCR-CAR dual signaling for precise cancer targeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近期，Kondo等人通过工程化方式使T细胞受体（TCR）与嵌合抗原受体（CAR）共表达，并开发了一种由拮抗作用强化的制动系统：TCR信号既可增强也可抑制CAR活化。这项工作或有助于合理设计CAR-T 药物，限制其对健康组织的毒性。
展开英文摘要原文
Recently, Kondo et al. engineered the coexpression of a T cell receptor (TCR) and a chimeric antigen receptor (CAR) and developed an antagonism-enforced braking system where TCR signals both enhance and inhibit CAR activation. This work may enable rational design of CAR-T agents that limit toxicity to healthy tissue.
论文信息
- 作者
- Shahbazy M、Leo IR、Faridi P、Caron E
- 第一作者单位
- Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.United States
- 通讯作者单位
- Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA; Yale Center for Immuno-Oncology, Yale Center for Systems and Engineering Immunology, Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA. Electronic address: etienne.caron@yale.edu.United States
- 期刊
- Trends in immunology2025 Jun
- 原文标识
- PubMed 40368698 · DOI 10.1016/j.it.2025.04.007